Real-world study demonstrates comparative effectiveness of dupilumab against benralizumab and mepolizumab in asthma, highlighting systemic corticosteroid reduction.
In the United States, this real-world study compared the effectiveness of dupilumab, benralizumab, and mepolizumab in reducing exacerbations and systemic corticosteroid (SCS) prescriptions among patients with asthma.
No takes yet. Share an insight, caveat, or question.
Bleecker et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: